PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21170080-9	2011	The expression of MMP-9, TIMP-1, and TGF-beta(1) in induced sputum samples increased in patients with asthma and decreased dramatically after treatment with formoterol-budesonide.	Budesonide	168-178	TIMP metallopeptidase inhibitor 1	Homo sapiens	25-31	
19786805-4	2010	Inhaled budesonide increased TIMP-1 levels in both groups of asthmatic children and normalized the MMP-8/TIMP-1 ratio, and this paralleled the improvement in forced expiratory volume in 1 s in children with mild symptoms.	Budesonide	8-18	TIMP metallopeptidase inhibitor 1	Homo sapiens	29-35	
19786805-4	2010	Inhaled budesonide increased TIMP-1 levels in both groups of asthmatic children and normalized the MMP-8/TIMP-1 ratio, and this paralleled the improvement in forced expiratory volume in 1 s in children with mild symptoms.	Budesonide	8-18	TIMP metallopeptidase inhibitor 1	Homo sapiens	105-111	
19786805-6	2010	Budesonide decreased the percentage of MMP-8-positive macrophages and increased that of TIMP-1-positive macrophages; these changes were significant in asthmatic children with mild symptoms.	Budesonide	0-10	TIMP metallopeptidase inhibitor 1	Homo sapiens	88-94	
19786805-7	2010	CONCLUSIONS: Inhaled budesonide normalized the MMP-8/TIMP-1 ratio in asthmatic children by upregulation of TIMP-1 production and downregulation of MMP-8 production by airway macrophages.	Budesonide	21-31	TIMP metallopeptidase inhibitor 1	Homo sapiens	53-59	
19786805-7	2010	CONCLUSIONS: Inhaled budesonide normalized the MMP-8/TIMP-1 ratio in asthmatic children by upregulation of TIMP-1 production and downregulation of MMP-8 production by airway macrophages.	Budesonide	21-31	TIMP metallopeptidase inhibitor 1	Homo sapiens	107-113	
19375904-6	2009	Concurrent budesonide/formoterol combination counteracted the enhanced: PG and TIMP-1 production, MMP-9 activity and MMP-9/TIMP-1 ratio, whereas MMP-2 and MMP-3 were not affected and so their ratios to TIMP-1 were significantly increased.	Budesonide	11-21	TIMP metallopeptidase inhibitor 1	Homo sapiens	123-129	
19375904-7	2009	Budesonide or formoterol alone achieved equal effects as budesonide/formoterol on MMP-9 and MMP-9/TIMP-1 ratio but had no effects on TIMP-1, MMP-2 or MMP-3.	Budesonide	0-10	TIMP metallopeptidase inhibitor 1	Homo sapiens	98-104	
19375904-9	2009	These results suggest that the budesonide/formoterol combination enhanced metalloproteolytic activity of human lung fibroblasts via a synergistic decrease of TIMP-1, and that this mechanism may be involved in the synergistic inhibition of the TGFbeta1-induced PG production.	Budesonide	31-41	TIMP metallopeptidase inhibitor 1	Homo sapiens	158-164	
19375904-6	2009	Concurrent budesonide/formoterol combination counteracted the enhanced: PG and TIMP-1 production, MMP-9 activity and MMP-9/TIMP-1 ratio, whereas MMP-2 and MMP-3 were not affected and so their ratios to TIMP-1 were significantly increased.	Budesonide	11-21	TIMP metallopeptidase inhibitor 1	Homo sapiens	79-85	
19375904-6	2009	Concurrent budesonide/formoterol combination counteracted the enhanced: PG and TIMP-1 production, MMP-9 activity and MMP-9/TIMP-1 ratio, whereas MMP-2 and MMP-3 were not affected and so their ratios to TIMP-1 were significantly increased.	Budesonide	11-21	TIMP metallopeptidase inhibitor 1	Homo sapiens	123-129	
34262692-11	2021	Interleukin (IL)-8, IL-10, IL-1alpha, and tissue inhibitor of metalloproteinase (TIMP)-1 concentrations were significantly increased in the culture medium of cells exposed to PM2.5, and budesonide significantly reduced the changes in IL-8, IL-1alpha, and TIMP-1.	Budesonide	186-196	TIMP metallopeptidase inhibitor 1	Homo sapiens	42-88	
34262692-11	2021	Interleukin (IL)-8, IL-10, IL-1alpha, and tissue inhibitor of metalloproteinase (TIMP)-1 concentrations were significantly increased in the culture medium of cells exposed to PM2.5, and budesonide significantly reduced the changes in IL-8, IL-1alpha, and TIMP-1.	Budesonide	186-196	TIMP metallopeptidase inhibitor 1	Homo sapiens	255-261